$NKTR
NEKTAR THERAPEUTICS

2023 Q4 Form 10-Q Financial Statement

#000095017023060475 Filed on November 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $23.89M $24.14M
YoY Change 8.45% 2.2%
Cost Of Revenue $7.283M $12.43M
YoY Change 16.85% 150.02%
Gross Profit $16.60M $11.71M
YoY Change 5.14% -37.21%
Gross Profit Margin 69.51% 48.51%
Selling, General & Admin $17.32M $21.10M
YoY Change -21.05% -6.36%
% of Gross Profit 104.32% 180.14%
Research & Development $29.94M $24.07M
YoY Change -13.81% -28.34%
% of Gross Profit 180.35% 205.5%
Depreciation & Amortization $1.615M $1.700M
YoY Change -49.25% -36.5%
% of Gross Profit 9.73% 14.51%
Operating Expenses $45.96M $24.07M
YoY Change -18.91% -28.34%
Operating Profit -$29.36M -$44.86M
YoY Change -28.2% -17.38%
Interest Expense -$2.350M -$1.000M
YoY Change -42.33% -79.6%
% of Operating Profit
Other Income/Expense, Net -$6.247M -$1.034M
YoY Change -78.91%
Pretax Income -$42.11M -$45.90M
YoY Change -25.53% -22.47%
Income Tax -$29.00K -$61.00K
% Of Pretax Income
Net Earnings -$42.08M -$45.84M
YoY Change -29.5% -22.37%
Net Earnings / Revenue -176.17% -189.85%
Basic Earnings Per Share -$0.24
Diluted Earnings Per Share -$0.22 -$0.24
COMMON SHARES
Basic Shares Outstanding 190.8M 190.1M shares
Diluted Shares Outstanding 190.4M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $303.6M $372.7M
YoY Change -39.88% -31.8%
Cash & Equivalents $35.28M $64.92M
Short-Term Investments $268.3M $307.7M
Other Short-Term Assets $9.779M $9.033M
YoY Change -38.14% -59.87%
Inventory $16.10M $15.13M
Prepaid Expenses
Receivables $1.205M $2.204M
Other Receivables $0.00 $0.00
Total Short-Term Assets $330.7M $399.0M
YoY Change -39.43% -33.44%
LONG-TERM ASSETS
Property, Plant & Equipment $18.86M $19.95M
YoY Change -41.89% -45.8%
Goodwill $0.00 $0.00
YoY Change -100.0% -100.0%
Intangibles
YoY Change
Long-Term Investments $25.83M
YoY Change
Other Assets $4.644M $4.523M
YoY Change 106.86% 94.71%
Total Long-Term Assets $67.33M $43.22M
YoY Change -59.1% -76.19%
TOTAL ASSETS
Total Short-Term Assets $330.7M $399.0M
Total Long-Term Assets $67.33M $43.22M
Total Assets $398.0M $442.2M
YoY Change -43.99% -43.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.848M $3.288M
YoY Change -24.13% -38.3%
Accrued Expenses $22.16M $29.73M
YoY Change -59.87% -62.21%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $51.27M $52.11M
YoY Change -24.83% -37.95%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.635M $4.961M
YoY Change -38.62% 62.44%
Total Long-Term Liabilities $4.635M $4.961M
YoY Change -38.62% 62.44%
TOTAL LIABILITIES
Total Short-Term Liabilities $51.27M $52.11M
Total Long-Term Liabilities $4.635M $4.961M
Total Liabilities $267.0M $282.9M
YoY Change -22.36% -23.29%
SHAREHOLDERS EQUITY
Retained Earnings -$3.477B -$3.435B
YoY Change 8.62% 9.35%
Common Stock $3.608B $3.601B
YoY Change 0.93% 1.09%
Preferred Stock
YoY Change
Treasury Stock (at cost) $0.00
YoY Change
Treasury Stock Shares
Shareholders Equity $131.0M $159.4M
YoY Change
Total Liabilities & Shareholders Equity $398.0M $442.2M
YoY Change -43.99% -43.38%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$42.08M -$45.84M
YoY Change -29.5% -22.37%
Depreciation, Depletion And Amortization $1.615M $1.700M
YoY Change -49.25% -36.5%
Cash From Operating Activities -$47.01M -$42.20M
YoY Change -18.54% -49.09%
INVESTING ACTIVITIES
Capital Expenditures $265.0K $0.00
YoY Change -48.24% -100.0%
Acquisitions
YoY Change
Other Investing Activities $17.63M $56.40M
YoY Change -56.5% -49.45%
Cash From Investing Activities $17.36M $56.40M
YoY Change -56.61% -49.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 30.00K 0.000
YoY Change -70.87%
NET CHANGE
Cash From Operating Activities -47.01M -42.20M
Cash From Investing Activities 17.36M 56.40M
Cash From Financing Activities 30.00K 0.000
Net Change In Cash -29.61M 14.20M
YoY Change 68.38% -50.19%
FREE CASH FLOW
Cash From Operating Activities -$47.01M -$42.20M
Capital Expenditures $265.0K $0.00
Free Cash Flow -$47.27M -$42.20M
YoY Change -18.8% -48.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Registrant Name
EntityRegistrantName
NEKTAR THERAPEUTICS
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0000906709
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
0-24006
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3134940
dei Entity Address Address Line1
EntityAddressAddressLine1
455 Mission Bay Boulevard South
dei Entity Address City Or Town
EntityAddressCityOrTown
San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94158
dei City Area Code
CityAreaCode
415
dei Local Phone Number
LocalPhoneNumber
482-5300
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
dei Trading Symbol
TradingSymbol
NKTR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
190770566
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64921000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
88227000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
307737000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
416750000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2204000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5981000
CY2023Q3 us-gaap Inventory Net
InventoryNet
15130000
CY2022Q4 us-gaap Inventory Net
InventoryNet
19202000
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
9033000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
15808000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
399025000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
545968000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19949000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32451000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18747000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
53435000
CY2023Q3 us-gaap Goodwill
Goodwill
0
CY2022Q4 us-gaap Goodwill
Goodwill
76501000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4523000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2245000
CY2023Q3 us-gaap Assets
Assets
442244000
CY2022Q4 us-gaap Assets
Assets
710600000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3288000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
12980000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
29729000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
36557000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
19095000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
18667000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
52112000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
68204000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
102193000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
112829000
CY2023Q3 nktr Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
123610000
CY2022Q4 nktr Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
155378000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4961000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7551000
CY2023Q3 us-gaap Liabilities
Liabilities
282876000
CY2022Q4 us-gaap Liabilities
Liabilities
343962000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0
CY2022Q4 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
190771000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
190771000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
188560000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
188560000
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
19000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
19000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3600871000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3574719000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6352000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6907000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3435170000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3201193000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
159368000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
366638000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
442244000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
710600000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24144000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
23625000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
66237000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
70032000
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
12431000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4972000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
26485000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
15402000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24070000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33590000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
84220000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
183583000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21147000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22534000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
60097000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
70394000
CY2023Q3 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
11360000
CY2022Q3 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
16830000
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
49107000
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
124350000
CY2023Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
76501000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
69008000
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
77926000
us-gaap Costs And Expenses
CostsAndExpenses
296410000
us-gaap Costs And Expenses
CostsAndExpenses
393729000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-44864000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-54301000
us-gaap Operating Income Loss
OperatingIncomeLoss
-230173000
us-gaap Operating Income Loss
OperatingIncomeLoss
-323697000
CY2023Q3 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
0
CY2022Q3 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
0
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
0
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
33427000
CY2023Q3 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
5910000
CY2022Q3 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
6953000
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
18467000
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
21710000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4876000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2050000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
14492000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3541000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1034000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4903000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3975000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
15258000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-45898000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-59204000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-234148000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-308439000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-61000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-155000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-171000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
71000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-45837000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-59049000
us-gaap Net Income Loss
NetIncomeLoss
-233977000
us-gaap Net Income Loss
NetIncomeLoss
-308510000
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.65
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
190406000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
190406000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
187641000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
187641000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
189651000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
189651000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
186767000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
186767000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-45837000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-59049000
us-gaap Net Income Loss
NetIncomeLoss
-233977000
us-gaap Net Income Loss
NetIncomeLoss
-308510000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
196000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
490000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1527000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-2589000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-98000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-468000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-972000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1423000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
98000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
22000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
555000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-4012000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-45739000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-59027000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-233422000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-312522000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
679508000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
188000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20961000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-92768000
CY2023Q3 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
372658000
CY2022Q4 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
504977000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1800000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
607889000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
467000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11103000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-160727000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
458732000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12518000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-59027000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
412223000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
366638000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10019000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-135792000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
240865000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
18000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7966000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-51891000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
196958000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8149000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-45739000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
159368000
us-gaap Profit Loss
ProfitLoss
-233977000
us-gaap Profit Loss
ProfitLoss
-308510000
nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
50860000
nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
52167000
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
18467000
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
21710000
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
0
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
33427000
nktr Non Cash Research And Development Expense
NonCashResearchAndDevelopmentExpense
0
nktr Non Cash Research And Development Expense
NonCashResearchAndDevelopmentExpense
4951000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26134000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
44582000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
6163000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
9848000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1854000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
36628000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
58521000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
76501000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
nktr Provision For Inventory Obsolescence
ProvisionForInventoryObsolescence
4444000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
12137000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
372000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3777000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-10960000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
372000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3256000
nktr Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
6078000
nktr Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
1423000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-4450000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-4861000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-9328000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4184000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-7517000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1602000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-145559000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-246304000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
372821000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
295439000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
494385000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
626424000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
628000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5164000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1245000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
122181000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
325821000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
18000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
655000
us-gaap Proceeds From Derivative Instrument Financing Activities
ProceedsFromDerivativeInstrumentFinancingActivities
0
us-gaap Proceeds From Derivative Instrument Financing Activities
ProceedsFromDerivativeInstrumentFinancingActivities
750000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1405000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-382000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-23306000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
80540000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88227000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25218000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64921000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
105758000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2656000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2023Q3 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
372700000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:5.84%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and generally reflect any changes in estimates in the period first identified.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Significant Concentrations</span></p><p style="text-indent:5.84%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our customers are primarily pharmaceutical companies that are located in the U.S. and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. We generally do not require collateral from our customers. We perform a regular review of our customers’ credit risk and payment histories, including payments made after period end. Historically, we have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t experienced credit losses from our accounts receivable. We have not recorded reserves for credit losses for the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and nine months ended September 30, 2023 and 2022, nor have recorded such an allowance as of September 30, 2023 or December 31, 2022.</span></p><p style="text-indent:5.84%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, various factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer’s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if various factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</span></p>
CY2023Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2022Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64921000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
88227000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
307737000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
416750000
CY2023Q3 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
372658000
CY2022Q4 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
504977000
CY2023Q3 us-gaap Cash
Cash
5428000
CY2022Q4 us-gaap Cash
Cash
8798000
CY2023Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1918000
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2575000
CY2023Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
12291000
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
10749000
CY2023Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
921000
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5878000
CY2023Q3 us-gaap Inventory Net
InventoryNet
15130000
CY2022Q4 us-gaap Inventory Net
InventoryNet
19202000
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
9033000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
15808000
CY2023Q3 nktr Depreciable Property Plant And Equipment Gross
DepreciablePropertyPlantAndEquipmentGross
107704000
CY2022Q4 nktr Depreciable Property Plant And Equipment Gross
DepreciablePropertyPlantAndEquipmentGross
154652000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
88243000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
124731000
CY2023Q3 nktr Depreciable Property Plant And Equipment Net
DepreciablePropertyPlantAndEquipmentNet
19461000
CY2022Q4 nktr Depreciable Property Plant And Equipment Net
DepreciablePropertyPlantAndEquipmentNet
29921000
CY2023Q3 us-gaap Construction In Progress Gross
ConstructionInProgressGross
488000
CY2022Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
2530000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19949000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32451000
CY2022Q4 us-gaap Goodwill
Goodwill
76501000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
76501000
CY2023Q3 us-gaap Goodwill
Goodwill
0
CY2023Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
76500000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11477000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9582000
CY2023Q3 nktr Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
4236000
CY2022Q4 nktr Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
12262000
CY2023Q3 nktr Liability To Collaboration Partners Current
LiabilityToCollaborationPartnersCurrent
4444000
CY2022Q4 nktr Liability To Collaboration Partners Current
LiabilityToCollaborationPartnersCurrent
3808000
CY2023Q3 nktr Accrued Contract Termination Costs Current
AccruedContractTerminationCostsCurrent
2624000
CY2022Q4 nktr Accrued Contract Termination Costs Current
AccruedContractTerminationCostsCurrent
3902000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6948000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7003000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
29729000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
36557000
CY2022Q4 nktr Liability Related To Sale Of Potential Future Royalties Non Current
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
155378000
nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
50860000
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
18467000
nktr Liabilities On Sale Of Future Royalties Amortized Transaction Costs
LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts
625000
CY2023Q3 nktr Liability Related To Sale Of Potential Future Royalties Non Current
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
123610000
CY2023Q3 us-gaap Litigation Reserve
LitigationReserve
0
CY2022Q4 us-gaap Litigation Reserve
LitigationReserve
0
CY2022Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
0
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
-53401000
nktr Impairment Long Lived Asset Held For Use Other
ImpairmentLongLivedAssetHeldForUseOther
5120000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
58521000
CY2023Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
76500000
CY2023Q1 nktr Impairment Long Lived Asset Held For Use Other
ImpairmentLongLivedAssetHeldForUseOther
1700000
nktr Gain Loss On Net Impairment On Sale Of Plant And Equipment
GainLossOnNetImpairmentOnSaleOfPlantAndEquipment
1300000
CY2023Q3 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
-10567000
CY2023Q3 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
394000
CY2023Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
10173000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
-35329000
nktr Impairment Long Lived Asset Held For Use Other
ImpairmentLongLivedAssetHeldForUseOther
1299000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
36628000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8149000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12518000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26134000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
44582000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
nktr-20230930_def.xml Edgar Link unprocessable
0000950170-23-060475-index-headers.html Edgar Link pending
0000950170-23-060475-index.html Edgar Link pending
0000950170-23-060475.txt Edgar Link pending
0000950170-23-060475-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nktr-20230930.htm Edgar Link pending
nktr-20230930.xsd Edgar Link pending
nktr-ex10_6.htm Edgar Link pending
nktr-ex31_1.htm Edgar Link pending
nktr-ex31_2.htm Edgar Link pending
nktr-20230930_cal.xml Edgar Link unprocessable
nktr-20230930_lab.xml Edgar Link unprocessable
nktr-20230930_pre.xml Edgar Link unprocessable
nktr-20230930_htm.xml Edgar Link completed
nktr-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending